Literature DB >> 28315377

Patient-derived xenografts: A platform for accelerating translational research in prostate cancer.

Alastair H Davies1, Yuzhuo Wang1, Amina Zoubeidi2.   

Abstract

Recently, there has been renewed interest in the development and characterization of patient-derived tumour xenograft (PDX) models. Numerous PDX models have been established for prostate cancer and, importantly, retain the principal molecular, genetic, and histological characteristics of the donor tumour. As such, these models provide significant improvements over standard cell line xenograft models for biological studies, preclinical drug development, and personalized medicine strategies. This review summarizes the current state of the art in this field, illustrating the opportunities and limitations of PDX models in translational prostate cancer research.
Copyright © 2017. Published by Elsevier B.V.

Entities:  

Keywords:  Cancer models; Drug discovery; Patient-derived xenograft; Personalized medicine; Prostate cancer; Translational research

Mesh：

Substances：

Year:  2017        PMID： 28315377     DOI： 10.1016/j.mce.2017.03.013

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN： 0303-7207            Impact factor:   4.102


  7 in total

Review 1.  Development of patient-derived xenograft models of prostate cancer for maintaining tumor heterogeneity.

Authors:  Changhong Shi; Xue Chen; Dengxu Tan
Journal:  Transl Androl Urol       Date:  2019-10

Review 2.  Proteomic discovery of non-invasive biomarkers of localized prostate cancer using mass spectrometry.

Authors:  Amanda Khoo; Lydia Y Liu; Julius O Nyalwidhe; O John Semmes; Danny Vesprini; Michelle R Downes; Paul C Boutros; Stanley K Liu; Thomas Kislinger
Journal:  Nat Rev Urol       Date:  2021-08-27       Impact factor: 14.432

3.  Critical evaluation of the subcutaneous engraftments of hormone naïve primary prostate cancer.

Authors:  Maija Valta; Jani Ylä-Pelto; Yu Lan; Tiina Kähkönen; Pekka Taimen; Peter J Boström; Otto Ettala; Sofia Khan; Niklas Paulin; Laura L Elo; Päivi J Koskinen; Pirkko Härkönen; Johanna Tuomela
Journal:  Transl Androl Urol       Date:  2020-06

Review 4.  Patient-derived tumour models for personalized therapeutics in urological cancers.

Authors:  Arjanneke F van de Merbel; Geertje van der Horst; Gabri van der Pluijm
Journal:  Nat Rev Urol       Date:  2020-11-10       Impact factor: 14.432

5.  Development and Characterization of a Spontaneously Metastatic Patient-Derived Xenograft Model of Human Prostate Cancer.

Authors:  Tobias Lange; Su Jung Oh-Hohenhorst; Simon A Joosse; Klaus Pantel; Oliver Hahn; Tobias Gosau; Sergey A Dyshlovoy; Jasmin Wellbrock; Susanne Feldhaus; Hanna Maar; Renate Gehrcke; Martina Kluth; Ronald Simon; Thorsten Schlomm; Hartwig Huland; Udo Schumacher
Journal:  Sci Rep       Date:  2018-12-03       Impact factor: 4.379

6.  Recapitulation of prostate tissue cell type-specific transcriptomes by an in vivo primary prostate tissue xenograft model.

Authors:  Nelson T Gross; Jianmin Wang; Michael V Fiandalo; Eduardo Cortes Gomez; Anica Watts; Alejandro S Godoy; Gary J Smith; Yue Wu
Journal:  PLoS One       Date:  2020-06-25       Impact factor: 3.240

7.  Establishment and characterization of patient-derived xenografts for hormone-naïve and castrate-resistant prostate cancers to improve treatment modality evaluation.

Authors:  Pengpeng Wu; Rong Xu; Xue Chen; Ya Zhao; Dengxu Tan; Yong Zhao; Weijun Qin; Caiqin Zhang; Xu Ge; Changhong Shi
Journal:  Aging (Albany NY)       Date:  2020-02-24       Impact factor: 5.682
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.